Literature DB >> 20111067

MPL mutation effect on JAK2 46/1 haplotype frequency in JAK2V617F-negative myeloproliferative neoplasms.

M M Patnaik, T L Lasho, C M Finke, N Gangat, D Caramazza, S Siragusa, C A Hanson, A Pardanani, A Tefferi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20111067     DOI： 10.1038/leu.2010.1

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  7 in total

1.  Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.

Authors:  Tiziano Barbui; Giovanni Barosi; Gunnar Birgegard; Francisco Cervantes; Guido Finazzi; Martin Griesshammer; Claire Harrison; Hans Carl Hasselbalch; Rudiger Hehlmann; Ronald Hoffman; Jean-Jacques Kiladjian; Nicolaus Kröger; Ruben Mesa; Mary F McMullin; Animesh Pardanani; Francesco Passamonti; Alessandro M Vannucchi; Andreas Reiter; Richard T Silver; Srdan Verstovsek; Ayalew Tefferi
Journal:  J Clin Oncol       Date:  2011-01-04       Impact factor: 44.544

2.  A randomized dose-escalation study to assess the safety, tolerability, and pharmacokinetics of ruxolitinib (INC424) in healthy Japanese volunteers.

Authors:  Yoichiro Ogama; Tomoko Mineyama; Asuka Yamamoto; Margaret Woo; Naomi Shimada; Taro Amagasaki; Kazuto Natsume
Journal:  Int J Hematol       Date:  2013-02-05       Impact factor: 2.490

Review 3.  A comprehensive review of pacritinib in myelofibrosis.

Authors:  Srdan Verstovsek; Rami S Komrokji
Journal:  Future Oncol       Date:  2015-09-14       Impact factor: 3.404

4.  IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.

Authors:  A Tefferi; T L Lasho; O Abdel-Wahab; P Guglielmelli; J Patel; D Caramazza; L Pieri; C M Finke; O Kilpivaara; M Wadleigh; M Mai; R F McClure; D G Gilliland; R L Levine; A Pardanani; A M Vannucchi
Journal:  Leukemia       Date:  2010-05-27       Impact factor: 12.883

Review 5.  Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.

Authors:  A Tefferi
Journal:  Leukemia       Date:  2010-04-29       Impact factor: 11.528

6.  Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium.

Authors:  A Tefferi; O Abdel-Wahab; F Cervantes; J D Crispino; G Finazzi; F Girodon; H Gisslinger; J Gotlib; J-J Kiladjian; R L Levine; J D Licht; A Mullally; O Odenike; A Pardanani; R T Silver; E Solary; T Mughal
Journal:  Blood Cancer J       Date:  2011-03-04       Impact factor: 11.037

Review 7.  The JAK2 GGCC (46/1) Haplotype in Myeloproliferative Neoplasms: Causal or Random?

Authors:  Luisa Anelli; Antonella Zagaria; Giorgina Specchia; Francesco Albano
Journal:  Int J Mol Sci       Date:  2018-04-11       Impact factor: 5.923
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.